Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Lipid Digestion

Lipid Digestion

Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.

Cholesterol: Significance and Regulation

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...

Lipid Catabolism

Lipid Catabolism

Triglycerides serve as crucial long-term energy storage molecules in microorganisms, providing a dense source of metabolic energy. Their breakdown is mediated by lipases, which hydrolyze triglycerides into glycerol and free fatty acids. Each of these components follows distinct metabolic pathways, ultimately contributing to ATP synthesis and cellular energy homeostasis.Glycerol MetabolismGlycerol, released from triglyceride hydrolysis, is phosphorylated by glycerol kinase to form...

Lipid Absorption

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Assessing the Benefits and Harms of Pharmacotherapy in Older Adults with Frailty: Insights from Pharmacoepidemiologic Studies of Routine Health Care Data.

Drugs & aging·2024

Same author

Geriatric Condition Burden in Cardiovascular Clinics.

JACC. Advances·2024

Same author

Neonatal dysregulation of 2-arachidonoylglycerol induces impaired brain function in adult mice.

Neuropharmacology·2024

Same author

Racial/ethnic differences in patients undergoing left atrial appendage occlusion.

Heart rhythm O2·2024

Same author

Needs and gaps of faculty development for medical schools.

Korean journal of medical education·2024

Same author

Providers' and survivors' perspectives on the availability and accessibility of surgery in gastrointestinal cancer care.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract·2024

Same journal

Extracellular Vesicles from Mesenchymal Stem Cells Alleviate Spinal Cord Injury via the miR-486-5p/PTEN/PI3K/AKT Pathway.

Current drug targets·2026

Same journal

Improving B-cell Linear Epitope Prediction <i>via</i> Multiple Feature Fusion and an Integrated Machine Learning Algorithm.

Current drug targets·2026

Same journal

Mechanistic Insights into the Inhibition of Plasmodium falciparum DNA Gyrase A by Withanolide Derivatives through Integrated Computational Analysis.

Current drug targets·2026

Same journal

Epitranscriptomics in Breast Cancer: The Unveiled Role of RNA Modifications.

Current drug targets·2026

Same journal

Neuroinflammation in Alzheimer's Disease: New Approaches.

Current drug targets·2026

Same journal

FXYD3: A Key Regulator of Ion Homeostasis and Redox Balance in Cancer Biology.

Current drug targets·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Targeting FoxO1 for hypertriglyceridemia.

Dae Hyun Kim¹, Ting Zhang, Steven Ringquist

¹Division of Immunogenetics, Rangos Research Center, Children's Hospital of Pittsburgh of UPMC, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15224, USA.

Current Drug Targets

|March 30, 2011

Summary

This summary is machine-generated.

Targeting FoxO1 in the liver may treat hypertriglyceridemia. Inhibiting FoxO1 improves triglyceride metabolism in insulin resistance, obesity, and type 2 diabetes.

More Related Videos

Assessing Whole-Body Lipid-Handling Capacity in Mice

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

Related Experiment Videos

Last Updated: Jun 3, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Assessing Whole-Body Lipid-Handling Capacity in Mice

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

Area of Science:

Lipid Metabolism
Endocrinology
Cardiovascular Disease Pathophysiology

Background:

Hypertriglyceridemia involves increased production and decreased clearance of triglyceride-rich lipoproteins (VLDL, chylomicron).
It is linked to obesity, type 2 diabetes, and insulin resistance, contributing to atherosclerosis.
The molecular link between insulin resistance and hypertriglyceridemia is not fully understood.

Purpose of the Study:

To review the role of FoxO1 in insulin action and lipid metabolism.
To evaluate targeting FoxO1 as a therapeutic strategy for hypertriglyceridemia.

Main Methods:

Review of preclinical studies on FoxO1's role in regulating MTP and ApoC-III.
Analysis of FoxO1's deregulation in insulin resistance and its impact on hepatic VLDL production and clearance.
Evaluation of therapeutic potential of selective hepatic FoxO1 inhibition.

Main Results:

FoxO1 regulates key steps in triglyceride-rich lipoprotein production and clearance.
Insulin resistance leads to deregulated FoxO1 activity, causing hepatic overproduction of VLDL.
Impaired catabolism of triglyceride-rich particles contributes to hypertriglyceridemia pathogenesis.

Conclusions:

FoxO1 deregulation in the liver is a key mechanism in hypertriglyceridemia pathogenesis.
Selective inhibition of hepatic FoxO1 activity offers a potential therapeutic approach.
Targeting FoxO1 may ameliorate hypertriglyceridemia in patients with obesity and type 2 diabetes.